The Digital Innovation Continuum: How Newer Digital Marketing Capabilities Can Prime an Organization for Digital Health Adoption
Digital Marketing Innovation can be used to support a broader array of near-term business objectives and customer needs, but if planned with purpose these solutions can also help to establish a roadmap for life science organizations to move toward adoption of longer-term, scalable digital health partnerships. Understand where your brand and organization are on the continuum and where to focus your innovation efforts for optimal return over the near, mid and long-term horizons.
Perspectives from Life Science marketers who have successfully commercialized Digital Health initiatives, and how an organization’s mindset about and experience with digital affects the approach
Humans have been telling stories for millennia, yet scientists and clinicians often find it hard to explain the value proposition of their science to venture capitalists and biopharma industry executives. This inability to describe research in a compelling way hinders healthcare startups from raising funds, attracting media attention, and connecting with future customers — but it doesn’t have to be so difficult. Using examples from journalism, big data analytics, and the real world, Ryan Flinn, a communications leader at Johnson & Johnson Innovation, will share the lessons he’s learned from nearly two decades as a storyteller, both as a journalist at Bloomberg News and as a media strategist.
HappifyDTx is a digital therapeutic company that addresses anxiety and mood disorders, which are comorbid with most chronic diseases pharma companies treat. HappifyDTx’s RCTs with over 2,000 participants and commercial contracts with the largest health plans and employers in the U.S.-led Sanofi to seek a partnership.
Understand why digital therapeutics is critical to the next phase of evolution in the pharmaceutical and biotech industry
Analyze partnerships at the center of the strategy
Discuss the diverse partnership relationship spanning R&D, clinical trials, regulatory approval, commercialization, and follow-on patient and technology support
Join Cassandra Clemens and Kate Miller in understanding how to utilize conversational marketing as a critical tool to enhance customer service, based on how today’s customers expect and prefer to receive support. You will learn how simple applications can evolve over time to gain contextual insights and deliver one-to-one conversations at scale.
A case study featuring how 2Morrow is offering digital behavioral therapy combined with GSK Nicotine Replacement Therapy to address nicotine addiction ● Real world examples of how 2Morrow and GSK use digital health to distribute OTC NRT ● Challenges and obstacles ● Lessons learned ● Data and results
Front-and back-end data has evolved greatly in the last 5 years. Today, new data science approaches are reshaping the promise of improved performance – is it worth the investment for pharma?
DH4P is about sharing, learning and gaining practical insights that enable pharma commercial teams leverage digital health to have an eventual commercial impact. The opening keynote applies what we learned since the infancy of digital health to form the basis of a new “digital health for pharma” market vision. We will share this vision for the future, including external healthcare, technology and commercial pharma dynamics, implications and digital opportunities along a continuum that can be leveraged by every life science organization from digitally naïve to digitally mature.
There is unbridled excitement and investment in digital health technologies, but relatively little evidence about whether they are improving patient outcomes or enhancing value of care. In this talk, Dr. Brennan Spiegel, Director of Health Services Research at Cedars-Sinai in Los Angeles, will discuss the evidence about what works—and what doesn’t work—using health technology in the clinical trenches. With examples ranging from use of virtual reality, to wearable biosensors, to smartphone applications, Dr. Spiegel will discuss the nitty-gritty details about their successes and failures using digital health in everyday care.
Recognizing how and when our industry should partner with the Digital Health Ecosystem to drive value for our customers and our brands. Understanding the complex dynamics of the changing healthcare landscape and the tremendous opportunities for Life Science organizations to adapt and evolve via external collaborations. Learn the Do’s and Don’ts and develop partnerships that dramatically enhance the value proposition of life science brands to drive commercial impact for those brands by achieving customer goals
How do we create a better experience for patients, clinical researchers, regulators and colleagues by modernizing clinical trials. Some real-life examples of where Pfizer has utilized technology to automate some highly manual processes, to create new experiences with patients through the use of digital technologies in clinical trials, integrate with EMR systems to reduce redundancy of data collection and to bring clinical trials to patients. A look at the successes and challenges, including change management, as we transform highly complex and regulated processes into more efficient and rewarding experiences.
Perspectives from an industry pioneer in digital on what it takes for life sciences organizations to drive successful (not easy) impact with Digital Health. Real life examples taken from the perspective of the Board and C-Suite on what pharma and digital health providers can and must do together to accelerate adoption and impact.
The average patient commutes one hour and sixteen minutes to get to their doctor’s appointment and waits another 19 minutes in the lobby for their doctor. The average wait time for a telemedicine patient to set up and wait? Six to nine minutes.
Telemedicine is redefining the customer experience and customer expectations. It’s up to us as pharma marketers to push boundaries – compliantly – and serve to the patient’s needs.
The Growth of Telemedicine:
The search for the right Telemed partner
Preparing your internal team for telemedicine;
Getting internal stakeholder buy-in
How does a pharma company partner with Telemed and stay compliant?
Dos and Don’ts
Examples of what works/what doesn’t
Patient Experience:
Why telemedicine is the right channel for women’s health;
Patient expectations
Starting out;
Training materials for HCPs
Where did we end up;
User case studies: Testing, issues, etc.
Key learnings
Campaign Execution
Consumer Messaging
How we position telemedicine on our owned properties
Creative Execution and where we promote and reach patients
Pre-Launch: Creating a “line-up” experience to drive early demand
Digital technology can transform both therapies and research beyond what we see today. The rapid evolution of wearable devices and mobile health technology is creating a marketplace that provides many options for digital healthcare. But which device is the best? They all are – depending on what you’re trying to do. The lack of know-how to understand and validate sensors, devices, data, and algorithms are preventing us from fulfilling the full promise of digital health. Learn how to begin making sense of sensors
In this session we will share an overview of EHRs, including an end-to-end user experience from a provider perspective. We will also highlight opportunities for pharmaceutical organizations and share best practices.
Come learn how is Bayer leveraging data and technology to develop better solutions for a growing and aging populating via different examples in health and agriculture.
Digital Health Interventions offer tremendous promise in increasing the value of life science brands is improving patient health outcomes, reducing overall costs of care and improving care quality. Learn from pioneers and thought-leaders in digital health about the best ways to approach creating and demonstrating this value to payers
Create a custom schedule.
Take it with you on mobile.
Get listed in the directory.
